Tirzepatide Associated With Improved Health-Related Quality of Life in Adults With Obesity or Overweight in SURMOUNT-4

What Was Tested

This randomized controlled trial paper looks at Tirzepatide.

The researchers evaluated the effect of continued tirzepatide treatment on health-related quality of life (HRQoL) in SURMOUNT-4.

Who Took Part

According to the abstract, 4, participants were involved.

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

HRQoL was assessed using patient-reported outcomes (PROs: SF-36v2, IWQOL-Lite-CT, EQ-5D-5L).

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Random assignment meant chance, not the researchers, decided who got Tirzepatide and who got the comparison, which limits bias.

Blinding on both sides kept the participants and researchers unaware of who received Tirzepatide.

The comparison arm used a placebo, so changes seen with Tirzepatide could be set against what happens without it.

What Was Measured

PubMed files the paper under topics including Quality of Life, Obesity, Overweight, Anti-Obesity Agents, Weight Loss, Patient Reported Outcome Measures and Tirzepatide.

The authors tagged it with the keywords patient‐reported outcomes and tirzepatide health‐related quality of life.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Tirzepatide in 4, participants.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2025 (Obesity (Silver Spring, Md.)), a journal based in United States.

More context: the Tirzepatide compound page, all human trials.